Avalo Therapeutics AVTX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -72.4%-22.4pp | -50.1%— | —— | —— | |
| Return on assets | -58.6%-17.7pp | -40.9%+75.1pp | -116.1%-42.7pp | -73.4%+62.8pp | |
| Liquidity | |||||
| Current ratio | 8.1×-11.8× | 20×+18.1× | 1.8×+1.1× | 0.7×-2.4× | |
| Quick ratio | 8.1×-11.8× | 20×+18.1× | 1.8×+1.1× | 0.7×-2.4× | |
| Cash ratio | 1.2×-18.1× | 19.4×+17.7× | 1.6×+1.0× | 0.6×-2.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×-0.3× | 0.3×— | —— | |
| Debt-to-assets | 0×0.0× | 0×-0.1× | 0.1×-0.4× | 0.5×0.0× | |
| Interest coverage | -16.8×+3.9× | -20.7×— | —— | —— | |
| Per Share | |||||
| Book value per share | $6.20-65.1% | $17.75— | —— | —— | |
| Valuation | |||||
| Market capitalization | $946.18M+1,783% | $77.74M+966% | $7.29M-84.6% | $47.45M-75.2% | |
| Enterprise value | $921.19M-1,342% | -$56.03M-3,493% | $1.65M-96.7% | $49.86M-70.9% | |
| Price / book | 13.8×+13.4× | 0.6×-0.4× | 1×— | —— | |
| Earnings yield | -9%-154pp | -45.2%+387pp | -432.4%-345pp | -87.8%-43.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Avalo Therapeutics's profit margins?
- Avalo Therapeutics (AVTX) runs a 182.0% gross margin and a -15536.1% operating margin, with a -7965.8% net margin.
- Where do Avalo Therapeutics's ratios come from?
- Every ratio is computed from Avalo Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
